PHP14 ACCESS WITH EVIDENCE DEVELOPMENT SCHEMES: A FRAMEWORK FOR THEIR DESIGN AND EVALUATION  by Staflnski, T et al.
Abstracts A83
PHP7
COMPARING POTENTIAL STRATEGIES TO ELIMINATING MEDICARE 
PART D’S COVERAGE GAP
Zhang Y
University of Pittsburgh, Pittsburgh, PA, USA
OBJECTIVES: Eliminating the Medicare’s coverage gap is on health reform’s agenda. 
This study compares the implications of current House and Senate bills on closing the 
donut hole as well as use of generic drugs on three outcomes: 1) proportion of beneﬁ-
ciaries entering and going through the gap, 2) duration in the gap, and 3) total and 
out-of-pocket annual pharmacy spending. METHODS: 2007 pharmacy data of a 
random sample of beneﬁciaries enrolled in a Medicare-Advantage Part D plan were 
used to evaluate these outcomes under three proposals: 1) reducing the size of the 
donut hole by $500 (Senate bill); 2) reducing the size of the donut hole by $500 and 
a 50% discount for brand-names used in the donut hole (House bill); and 3) switching 
to generic drugs after several brand-names go off-patent by end-2011. RESULTS: 
Under 2007 Part D, 20% beneﬁciaries entered the gap and 3.5% entered the cata-
strophic period. People stayed in the gap for 132 days; their total pharmacy spending 
was $4561, with $2337 out-of-pocket and $2224 by Medicare. Under the Senate bill, 
14% would enter and 3.5% would go through the gap. Those entering the gap would 
stay there for 120 days and their total pharmacy spending would be $5214, $2788 
out-of-pocket and $2426 by Medicare. The House bill would save additional $791 
among beneﬁciaries entering the gap. Several blockbusters including Lipitor, Zyprexa, 
Prevacid, Novasc, Aricept will go off-patents by end-2011. If patients switched to their 
generic counterparts, 17% would enter the gap and 1.8% would enter the catastrophic 
period. The average gap duration would be 128 days. People entering the gap would 
spend $4476 total, $2115 out-of-pocket and $2361 by Medicare. CONCLUSIONS: 
Reducing the gap size can delay entering the gap, but may not reduce beneﬁciaries’ 
out-of-pocket spending. A strategy combining it with generic use could be more 
effective.
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BENEFICIARY CHOICE IN MEDICARE PART D
King AJ
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To empirically assess the preferences of Medicare beneﬁciaries in their 
selection of an approved Part D prescription drug plan. METHODS: A descriptive 
analysis illustrated the tendencies of those Part D beneﬁciaries who independently 
chose their 2007 Part D plan to keep their previous drug coverage and to consider 
other available Part D plans. The ﬁnal study sample included the 2007 Internet survey 
respondents who (by October 2007) were at least 65 years old and insured through 
Medicare Part D and excluded the Part D beneﬁciaries automatically enrolled in a 
Part D plan. This study was cross-sectional, using 2007 Internet Survey data from the 
Health and Retirement Study. A logistic regression model measured the collective 
explanatory power of a set of six variables describing beneﬁciary formulary prefer-
ences, a variable describing beneﬁciary plan knowledge, and a set of three demo-
graphic variables in determining beneﬁciaries’ choice to keep their prior Part D drug 
plan. The outcome and explanatory variables, except for two demographic variable 
representing respondent wealth and age, were coded as binary. RESULTS: Due to 
missing values, a total of 74 part D beneﬁciaries were included in this study. Of the 
Part D beneﬁciaries who independently chose their 2007 plan coverage, 82.8% kept 
their same coverage in 2007 as in 2006 and 71.9% looked at other available formulary 
plans. The likelihood ratio chi-square score of 21.38 (p < 0.0186) showed our logistic 
regression model to be statistically signiﬁcant. 2007 Part D beneﬁciaries with clear 
preferences for insurance company reputation and plans with gap coverage were 83.84 
(p < 0.019) and 0.03 (p < 0.041) times as likely to hold onto their 2006 coverage. 
CONCLUSIONS: In order to assess the efﬁciency of the Part D program, it is impor-
tant to understand the important factors surrounding beneﬁciary choice.
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COST CONSEQUENCE ANALYSIS OF PRESCRIPTION DRUG LABEL 
CHANGES
Zargarzadeh AH, Law AV
Western University of Health Sciences, Pomona, CA, USA
OBJECTIVES: According to a mandate, all California pharmacies will be changing 
to a new “patient centered “prescription label beginning January 2011. An increase 
in label size may be needed to comply with possible additional information/format 
changes that are being considered. This cost consequence study explored the impact 
of label changes to California pharmacies and projected to all US pharmacies. 
METHODS: A cost model was built based on input from 3 experts. It included: 1) 
continuing costs: bottle, cap or closure, label (dual web sheet paper vs. thermal roll, 
paper used, glue used), and 2) One-time costs: software program, additional storage 
area and staff training. Average additional costs for increasing bottle size from 13 
dram to 30 dram, increasing label size and added adhesive was estimated to be 10.5 
cents. A literature search conducted to estimate consequence of label change identiﬁed 
only two articles that addressed the impact of a new commercial label on health 
outcomes and medication safety. RESULTS: The additional costs to pharmacies for 
the new label would be close to $34 million ($372M for US) assuming 324 million 
prescriptions are ﬁlled by retail and mail order pharmacies annually in California (3.54 
billion for US). On average, each of 6000 California pharmacies will incur additional 
costs of $5700 dollars each year. Software changes were assumed to be zero cost. 
Additional storage and employee training were dealt with differently by each phar-
macy hence were used as parameters for a sensitivity analysis. The two studies on 
consequence did not show any signiﬁcant difference in impact on outcomes between 
using the new label and a traditional label. CONCLUSIONS: Additional costs of label 
change per pharmacy may not be considered signiﬁcant; however these costs could be 
transferred to patients as pharmacies are already experiencing ﬁnancial constraints.
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THE RELATIONSHIP OF RESEARCH AND DEVELOPMENT ACTIVITY 
WITH U.S. MEDICAL DRUG SHORTAGES
Stino M, McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA
OBJECTIVES: In an earlier study, we explored the characteristics of the medical drugs 
and devices in short supply on or before June 1, 2009. In this study, we looked at the 
internal characteristics of the individual manufacturers for those drugs. In addition, 
we examined the possible association for ﬁrms with signiﬁcant research and develop-
ment (R&D) operations and the number and average length of shortages. METHODS: 
We assembled an expert panel to determine the R&D status of these ﬁrms based on 
whether or not their primary mission was to develop novel drugs. We conducted 
statistical analyses to test several null hypotheses: 1) that there is no association 
between a ﬁrm’s R&D activity and the number of drugs in short supply for which it 
is listed; 2) that there is no association between a ﬁrm’s R&D activity and the average 
length of its shortages; 3) that there is no difference between ﬁrms with signiﬁcant 
R&D operations and other ﬁrms in regard to the number of shortages for which they 
are listed; and 4) that there is no difference between ﬁrms with signiﬁcant R&D 
operations and other ﬁrms in regard to the average duration of their shortages. 
RESULTS: We failed to reject the null hypotheses for overall, active, and resolved 
shortages, except in one case. We found that there was no signiﬁcance in most of these 
associations except in the relationship between a ﬁrm’s R&D status and the length of 
its resolved shortages. CONCLUSIONS: Based on this data, these results suggest that 
ﬁrms classiﬁed as being research-intensive did not have signiﬁcantly more drugs in 
short supply or longer durations for current and overall shortages. Firms focused on 
R&D had longer resolved shortages. We intend to continue investigating other manu-
facturer characteristics and their possible association with shortages.
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MEDICARE PART D AND ITS IMPACT ON PRESCRIPTION DRUG USE
Khan N1, Kaestner R2
1University of New Mexico Health Sciences Center, Albuquerque, NM, USA, 2University of 
Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Signiﬁcant fraction (approximately 30%) of elderly were without 
prescription drug coverage prior to Medicare Part D. Medicare Part D provided a 
subsidized prescription drug beneﬁt to all elderly beneﬁciaries. The objective of this 
study is to estimate the impact of part D on prescription drug utilization. METHODS: 
The analysis uses 2000–2006 Medicare Current Beneﬁciary Survey (MCBS). MCBS is 
nationally representative survey of elderly and disabled individuals. The survey con-
tains detailed information on prescription drug coverage, prescription drug utilization, 
and other sociodemographic, economic variables. The sample was limited to those age 
65–85 years with complete year of data, either uninsured or who had private coverage. 
Prescription drug coverage was calculated for each month, if respondent had coverage 
for at least 6-months they were assumed to be privately insured. We estimate the 
likelihood of being uninsured using pre Medicare part D data from 2000–2003. We 
then compared changes in prescription utilization pre- to post Medicare Part D for 
those more and less likely to be uninsured prior to Part D. RESULTS: In year 2005, 
approximately 30% of our sample did not have any prescription drug coverage. After 
part D was introduced, only 10% of the sample report not having any prescription 
drug coverage. On an average, total number of prescription used increased by 5 from 
2005–2006. Part D also included discount cards which were introduced in June 2004. 
The results indicated that discount cards increased the number of prescriptions by 3. 
Therefore, total impact of part D was approximately 8 more prescriptions. These 
results were supported in multivariate models (p = 0.01) controlling for various 
demographic and economic factors. CONCLUSIONS: Medicare part D increased 
prescription drug use signiﬁcantly among elderly non-Medicaid population. Future 
analysis should assess the impact of part D on health care utilization and health.
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ACCESS WITH EVIDENCE DEVELOPMENT SCHEMES: A FRAMEWORK 
FOR THEIR DESIGN AND EVALUATION
Staﬁnski T1, McCabe C2, Menon D1
1University of Alberta, Edmonton, AB, Canada, 2University of Leeds, Leeds, West Yorkshire, 
UK
OBJECTIVES: In recent years, efforts to balance access to promising, new technologies 
with the need to ensure effective and efﬁcient use of limited health care resources have 
focussed on the adoption of various forms of conditional coverage arrangements, 
collectively referred to as Access with Evidence Development (AED) schemes. While 
such arrangements continue to attract interest, concerns over ‘value for money’ have 
also been raised, since they often require considerable, committed resources for imple-
mentation. This project aimed to develop a framework for guiding the design of future 
AED schemes and apply this framework to the evaluation of existing AED schemes. 
METHODS: An international workshop involving researchers and decision-makers 
with experience designing and implementing AED schemes was held. Presentations 
comprising case studies from Australia, Canada, the UK, and the US were used to 
highlight issues/challenges and lessons learnt. They were followed by discussions 
around the strengths/weaknesses and resource requirements of such schemes. Based 
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on these ﬁndings, a framework consisting of key characteristics of an AED scheme 
was developed and, subsequently, applied to an inventory of existing AED schemes, 
compiled through a comprehensive review of relevant peer-reviewed and ‘grey’ litera-
ture available as of August 2009. RESULTS: The framework contained 11 character-
istics of AED schemes grouped into 3, sequential categories: 1) System level (Decision 
problem; Objective; Engagement; Evaluation); 2) Organisational (Governance; 
Financing); and 3) Research design (Scope; Level of Operation; Test Criterion; Test 
Implementation; Response to Test Result). It was applied to the inventory in the form 
of a checklist, similar to other critical appraisal tools. In general, information found 
for each of the schemes was limited and did not address questions comprising the 
checklist. CONCLUSIONS: Information upon which to evaluate AED schemes is 
sparse, yet necessary for moving forward with efforts to ensure their use represents 
value for money.
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EVALUATION OF PATIENT ASSISTANCE PROGRAM AVAILABILITY 
AND ELIGIBILITY FOR TOP 200 BRAND AND GENERIC DRUGS IN THE 
UNITED STATES
Chu CF1, Lal L2, Felder T1, Rosenau P1
1The University of Texas Health Science Center at Houston—School of Public Health, 
Houston, TX, USA, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 
USA
OBJECTIVES: This study examines the availability of and eligibility requirements for 
pharmaceutical patient assistance programs (PAPs) for the most commonly prescribed 
medications in the United States. METHODS: RxAssist.org, an electronic database of 
PAPs, was utilized to collect information on the availability (brand and/or generic) 
and eligibility (citizenship, permanent residency, insurance, and income limits) for each 
of the “Top 200 drugs by dispensed prescriptions” for 2008. Pharmaceutical compa-
nies were contacted directly or their websites were searched when additional clariﬁca-
tions were needed. Chi-square analyses were used to assess for differences in eligibility 
requirements by drug availability (brand or generic). RESULTS: Of 136 unique chemi-
cal entities, 111 (81.6%) of these drugs were available in RxAsisst.org. 69 (62.2%) 
of the available drugs were brand only, 29 (26.1%) generic only and 13 (11.7%) had 
both brand/generic forms. There were differences found in PAP eligibility requirements 
for citizenship (p < 0.001), permanent residency (p < 0.001), and private insurance 
status (p < 0.001) by drug availability (brand versus generic), but not for income limits 
(p = 0.051). Some programs allow Medicare Part D patients to apply for PAP; 
however, each claim is evaluated on case-to-case basis. CONCLUSIONS: Both brand 
and generic drugs are widely available to low-income applications through PAPs, but 
results suggest that U.S. citizenship and permanent residency are more likely to be 
required by PAPs for brand versus generic drugs. PAPs also provide some options for 
the underinsured—those with either private insurance or Medicare Part D coverage.
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LOW SOCIOECONOMIC STATUS IS A RISK FACTOR FOR CPAP 
ACCEPTANCE AMONG ADULT OSAS PATIENTS REQUIRING 
TREATMENT
Simon-Tuval T1, Reuveni H1, Greenberg-Dotan S1, Oksenberg A2, Tal A3, Tarasiuk A3
1Ben-Gurion University, Beer-Sheva, Israel, 2Loewenstein Hospital-Rehabilitation Center, 
Ra’anana, Israel, 3Soroka University Medical Center, Beer-Sheva, Israel
OBJECTIVES: To evaluate whether socioeconomic status (SES) plays a role in the 
patient’s decision to accept (purchase) continuous positive airway pressure (CPAP) 
treatment for obstructive sleep apnea syndrome (OSAS) (according to the Israeli 
National Health Insurance Law, purchasing CPAP treatment requires an out-of-pocket 
payment). METHODS: Cross-sectional prospective study in the University-afﬁliated 
Sleep Disorder Center in Beer-Sheva, Israel. Adult patients (age > 18 years), suspected 
of having OSAS, were consecutively recruited between March 2007 and December 
2007. Questionnaires were completed prior to diagnosis to elicit socioeconomic status, 
sleeping habits, and access to sources of information on OSAS and its treatments. At 
the conclusion of the adaptation period, a second questionnaire was completed to 
explore the reasons for commencing or declining treatment. RESULTS: Among the 
newly diagnosed (polysomnographically) adult OSAS patients, 162 required CPAP 
and underwent attendant titration and a 2-week adaptation period. Only 40% of these 
patients (n = 65) decided to purchase CPAP therapy. They were older, and typically 
they had higher apneahypopnea indexes (AHIs) and higher income levels than the 
patients who declined CPAP treatment. Multivariate logistic regression (adjusting for 
body mass index and Epworth Sleepiness Scale) revealed that whether a patient pur-
chased CPAP was determined by (OR, 95% CI): income level (2.4; 1.2–4.6), age (+1 
year) (1.07; 1.01–1.1), AHI (≥ 35 vs. < 35 events/hr) (4.2, 1.4–12.0), receiving positive 
feedback about the experiences of family or friends with CPAP (2.9, 1.1–7.5), and 
sleeping separate from spouse (4.3, 1.4–13.3). CONCLUSIONS: In addition to the 
already known determinants of CPAP acceptance, patients with low SES were less 
receptive to CPAP treatment than those with higher SES. CPAP support and patient 
education programs should be tailored for low SES people in order to increase rates 
of treatment initiation and adherence.
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WHAT FACTORS PREDICT FAVORABLE MEDICARE COVERAGE?
Chambers JD1, Neumann PJ1, Buxton M2
1Tufts Medical Center, Boston, MA, USA, 2HERG, Brunel University, Uxbridge, 
Middlesex, UK
OBJECTIVES: There is a lack of understanding and empirical basis regarding what 
factors are important in the Medicare National Coverage Determination (NCD) deci-
sion making process. The objective of this study was to determine what factors predict 
favorable coverage decisions. METHODS: NCDs from 1999 through 2007 were 
reviewed using publicly available decision memoranda posted on the CMS website (n 
= 140). Data abstracted from decision memoranda were supplemented with cost-
effectiveness information identiﬁed from an independent literature review. When a 
decision memo included coverage decisions for multiple technologies or indications, 
an entry was made for each coverage decision in the memorandum. The United States 
Preventative Services Task Force (USPSTF) guidelines were used to grade the support-
ing clinical evidence. We created a dataset with the following variables: quality of 
supporting clinical evidence; availability of alternative interventions; cost-effectiveness 
of intervention; intervention type, and coverage requestor. Logistic regression was 
used to determine what variables predicted favorable coverage. RESULTS: Good 
quality supporting clinical evidence was associated with an odds ratio (OR) of favor-
able coverage (95% CI) of 12.74 (3.02–53.74). Interventions estimated to be domi-
nant, i.e. less costly and more effective, or have an estimate of cost-effectiveness of < 
$50k per QALY were associated with an OR of 18.86 (4.62–77.00) and 3.91 (1.00–
15.40) respectively. Availability of alternative interventions for the same indication 
was associated with a decreased likelihood of coverage with an OR of 0.01 (0.03–
0.33). Type of intervention, and coverage requestor were not signiﬁcant predictors. 
CONCLUSIONS: The ﬁndings suggest that good quality supporting clinical evidence 
and favorable estimates of cost-effectiveness predict favorable CMS coverage deci-
sions. The availability of alternative interventions for the same indication reduced the 
likelihood of a favorable coverage decision. The ﬁndings indicate that Medicare’s 
coverage process is evidence and value-based, though more research is needed on the 
impact of decisions.
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EVALUATION OF MEDICARE PART D PHARMACY AND MEDICAL 
UTILIZATION PATTERNS BY COVERAGE PHASE FOR COMMON 
CHRONIC DISEASES
Priest J1, Sklar A2, Engel-Nitz N2, Shenolikar R1, Cantrell C1
1GlaxoSmithKline, RTP, NC, USA, 2i3 Innovus, Eden Prairie, MN, USA
OBJECTIVES: To evaluate the percent of patients reaching the coverage gap and 
catastrophic phase and their pharmacy and medical utilization for the treatment of 
common conditions (asthma, COPD, coronary artery disease, depression, diabetes, 
hyperlipidemia, hypertension (HTN), heart failure (HF)) among patients enrolled in 
Medicare Advantage with Part D coverage (MAPD). METHODS: Retrospective 
claims analysis using medical/pharmacy claims and enrollment data from a large 
National US Plan offering MAPD beneﬁts. Patients with full-year enrollment in 2007 
and ≥1 select condition based on claims in 2006 were identiﬁed. Phase transitions 
were based on pharmacy expenditures and low income subsidy and dually eligible 
patients were excluded. Outcomes included the proportion of patients ﬁlling any 
medication per national guidelines, proportion of days covered (PDC) for patients 
ﬁlling ≥1, compliance (MPR) for patients ﬁlling ≥2 and medical utilization/costs overall 
and by phase. RESULTS: The percentage of patients reaching the coverage gap ranged 
by condition from 18%–36% with 2%–6% reaching catastrophic. For all conditions, 
pharmacy utilization was lower in the coverage gap however, patients ﬁlling medica-
tions in the gap spent on average 8%(HTN) to 160%(depression) more out-of-pocket 
compared to their coinsurance phase. As with pharmacy utilization, medical also 
decreased during the coverage gap. Overall, the proportion of patients ﬁlling any 
acceptable medication for their condition ranged from 40%(COPD) to 95%(HF). The 
proportion of those with ≥80% PDC ranged from asthma(19%) to HF(76%) while 
compliance rates for patients reﬁlling (MPR ≥ 80%) ranged from Asthma(37%) to 
HF(87%). CONCLUSIONS: A fairly high percent of patients reached the coverage 
gap in 2007 and incurred substantially larger out-of-pocket expenses. Once in the gap, 
both medical and pharmacy utilization on average decreased. Medication compliance/
persistence was less than optimal overall and with up to one-third of patients reaching 
the gap there is further potential for reduced quality care that could negatively impact 
the health of an aging population.
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PREVALENCE AND PREDICTORS OF ANTIDEPRESSANT PRESCRIBING 
IN ELDERLY NURSING HOME RESIDENTS IN THE UNITED STATES
Karkare SU, Bhattacharjee S, Kamble P, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: This study examined the prevalence of antidepressant drug use and 
factors associated with their use among elderly nursing home residents in the Unites 
States using the 2004 National Nursing Home Survey (NNHS) data. METHODS: The 
study involved analysis of prescription and resident ﬁles of a nationally representative 
sample of residents aged ≥65 years from the 2004 NNHS data. The analysis focused 
on the prescribing of any antidepressant, including selective serotonin reuptake inhibi-
tors (SSRI), tricyclic antidepressants (TCAs), serotonin modulators, serotonin-norepi-
nephrine reuptake inhibitor (SNRI), MAO (Monoamine oxidase) inhibitors and 
‘other’ antidepressants such as mirtazapine and bupropion. A descriptive weighted 
analysis was performed to examine the prevalence patterns. Multiple logistic regres-
